OCULAR THERAPEUTIX Business Summary

Ocular Therapeutix, Inc. (OCUL) is an integrated biopharmaceutical company that generates revenue through the commercial sale of DEXTENZA, a bioresorbable intracanalicular insert for post-surgical ocular inflammation and pain, and through strategic collaboration agreements. The company’s business is bifurcated into its commercial segment and its advanced clinical pipeline, which utilizes the proprietary ELUTYX bioresorbable hydrogel platform to develop long-acting therapies. Its lead asset, AXPAXLI (OTX-TKI), is currently in Phase 3 development for wet age-related macular degeneration (wet AMD) and non-proliferative diabetic retinopathy (NPDR), targeting a 6-to-12-month dosing interval to improve patient compliance. Ocular Therapeutix competes directly with established retinal therapy giants such as Regeneron Pharmaceuticals (EYLEA), Roche (Vabysmo), and Novartis, positioning itself as a disruptive innovator in the retina space by leveraging sustained-release technology to challenge the current standard of frequent intravitreal injections. The leadership team is led by Executive Chairman, President, and CEO Pravin U. Dugel, MD, a world-renowned retina specialist and former clinical advisor to Novartis and Roche. Key executives include interim Chief Financial Officer Jason Robins, who assumed the role in January 2026, Chief Technical Officer Peter Jarrett, PhD, an expert in hydrogel chemistry, and Chief Scientific Officer Jeffrey S. Heier, MD. The executive ranks were recently bolstered by Global Chief Commercial Officer David W. Robinson, a key architect of the EYLEA launch at Regeneron. Founded by serial med-tech entrepreneur Amarpreet Sawhney, the company is backed by prominent institutional investors including FMR LLC (Fidelity), Deep Track Capital, and BlackRock, with a board of directors that includes industry veterans like Adrienne Graves, PhD, and Richard Lindstrom, MD.